Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Study Overview

• Status: Active, not recruiting
• Conditions: Small-cell Lung Cancer; Extensive-stage Small-cell Lung Cancer
• Intervention / Treatment: Drug: Paclitaxel; Drug: Carboplatin; Drug: Etoposide; Drug: BNT327 Dose Level 1 (DL1); Drug: BNT327 Dose Level 2 (DL2); Drug: Topotecan

Detailed Description

In Cohort 1 of this study, two dose levels of BNT327 will be studied in combination with etoposide and carboplatin to identify an optimized dose for future clinical investigation.

Cohort 2 and Cohort 3 will explore the combination of two dose levels of BNT327 with paclitaxel, or topotecan in the second- or third-line setting.

Patients will be treated until disease progression, intolerable toxicity, patient withdrawal, study termination or up to 2 years (whichever occurs first).

Participants will be assigned to either Cohort 1 or Cohort 2/Cohort 3 based on their disease type (i.e., untreated ES-SCLC for Cohort 1 and SCLC which has progressed on first- or second-line treatment for Cohort 2 and Cohort 3). Assignment to either Cohort 2 or Cohort 3 will be the investigator's choice.

Participants will be randomized to each arm within each cohort:

• Participants enrolled to Cohort 1 and Cohort 3 will be randomized in a 1:1 ratio to Arm 1 or Arm 2.
• Participants enrolled to Cohort 2 will be randomized in a 2:1 ratio to Arm 1 or Arm 2.

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Adelaide, Australia, 5112
    • Lyell McEwin Hospital
  • Fitzroy, Australia, 3065
    • St. Vincent's Hospital
  • Frankston, Australia, 3199
    • Peninsula Oncology Centre
  • St Leonards, Australia, 2065
    • Royal North Shore Hospital
  • Westmead, Australia, 2145
    • Westmead Hospital
• South Korea
  • Cheongju-si, South Korea, 28644
    • Chungbuk National University Hospital
  • Daegu, South Korea, 42415
    • Yeungnam University Medical Center
  • Goyang-si, South Korea, 10408
    • National Cancer Center
  • Incheon, South Korea, 21565
    • Gachon University Gil Medical Center
  • Jinju, South Korea, 52727
    • Gyeongsang National University Hospital (GNUH)
  • Seoul, South Korea, 03722
    • Severance Hospital, Yonsei University Health System
  • Seoul, South Korea, 02841
    • Korea University Anam Hospital
  • Seoul, South Korea, 06591
    • The Catholic University of Korea Seoul St. Mary'S Hospital
  • Suwon, South Korea, 16499
    • Ajou University Hospital
• Turkey (Türkiye)
  • Adana, Turkey (Türkiye), 01120
    • Baskent University Hospital Adana Dr Turgut Noyan Research Center
  • Adana, Turkey (Türkiye), 01230
    • Medical Park Seyhan Hospital
  • Adana, Turkey (Türkiye), 4522
    • Adana City Training and Research Hospital
  • Ankara, Turkey (Türkiye), 06800
    • Ankara City Hospital
  • Ankara, Turkey (Türkiye), 06010
    • Gulhane Egitim ve Arastirma Hastanesi
  • Ankara, Turkey (Türkiye), 06170
    • Ankara Etlik Sehir Hastanesi
  • Ankara, Turkey (Türkiye), 06200
    • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
  • Ankara, Turkey (Türkiye), 06230
    • Hacettepe University Medical Faculty Oncology Hospital
  • Ankara, Turkey (Türkiye), 06520
    • Memorial Ankara Hospital
  • Ankara, Turkey (Türkiye), 06680
    • Liv Hospital
  • Gaziantep, Turkey (Türkiye), 36020
    • Gaziantep Sanko University Medical Faculty
  • Istanbul, Turkey (Türkiye), 34722
    • Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
  • Istanbul, Turkey (Türkiye), 34010
    • Koc Universitesi Hastanesi (Koc University Hospital)
  • Istanbul, Turkey (Türkiye), 34093
    • Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
  • Istanbul, Turkey (Türkiye), 34457
    • Acibadem Adana Hastanesi
  • Istanbul, Turkey (Türkiye), 34718
    • Yeditepe University Kosuyolu Hospital
  • Izmir, Turkey (Türkiye), 35325
    • Medical Point Izmir Hospital
  • Kocaeli, Turkey (Türkiye), 41380
    • Kocaeli Universitesi Tip Fakultesi
  • Sakarya, Turkey (Türkiye), 54290
    • Sakarya University - Faculty of Medicine
  • Tekirdağ, Turkey (Türkiye), 59030
    • Namik Kemal University Hospital
  • Yenimahalle, Turkey (Türkiye), 06560
    • Gazi University Medical Faculty
• United Kingdom
  • Birmingham, United Kingdom, B15 2GW
    • Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust
  • Cardiff, United Kingdom, CF14 2TL
    • Velindre Hospital - Velindre NHS Trust
  • Dundee, United Kingdom, DD1 9SY
    • Ninewells Hospital and Medical School - Tayside Health Board
  • Exeter, United Kingdom, EX2 5DW
    • Royal Devon and Exeter Hospital, Wonford - Royal Devon And Exeter NHS Foundation Trust
  • Huddersfield, United Kingdom, HD3 3EA
    • Huddersfield Royal Infirmary - Calderdale and Huddersfield NHS Foundation Trust
  • Leeds, United Kingdom, LS9 7TF
    • St James'S University Hospital - Leeds Teaching Hospitals Nhs Trust
  • London, United Kingdom, W1G 6AD
    • Sarah Cannon Research Institute
  • Newcastle upon Tyne, United Kingdom, NE7 7DN
    • Northern Centre for Cancer Care,The Newcastle Upon Tyne Hospitals NHS Foundation Trust
  • Nottingham, United Kingdom, NG5 1PB
    • Nottingham University Hospitals NHS Trust
  • Preston, United Kingdom, PR2 9HT
    • Royal Preston Hospital - Lancashire Teaching Hospitals NHS Foundation Trust
  • Stoke-on-Trent, United Kingdom, ST4 6QG
    • Royal Stoke University Hospital - University Hospitals of North Midlands NHS Trust
• United States
  • Alaska
    • Anchorage, Alaska, United States, 99508
      • Alaska Oncology and Hematology, LLC
  • California
    • Los Angeles, California, United States, 90067
      • Valkyrie Clinical Trials
  • Florida
    • Clermont, Florida, United States, 34711
      • Clermont Oncology Center
    • Port Saint Lucie, Florida, United States, 34952
      • Hematology Oncology Associates of Treasure Coast
    • Tallahassee, Florida, United States, 32308
      • Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists
  • Illinois
    • Urbana, Illinois, United States, 61801
      • Carle Foundation Hospital d/b/a Carle Cancer Center
  • Indiana
    • Fort Wayne, Indiana, United States, 46804
      • Fort Wayne Medical Oncology and Hematology, Inc
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center)
  • Minnesota
    • Minneapolis, Minnesota, United States, 55407
      • Allina Health
  • Missouri
    • Fenton, Missouri, United States, 63026
      • SSM Health Cancer Care - St. Clare
  • Nebraska
    • Lincoln, Nebraska, United States, 68506
      • Nebraska Hematology-Oncology (NHO) - Lincoln
  • New York
    • Westbury, New York, United States, 11590
      • Clinical Research Alliance Inc
  • North Carolina
    • Clyde, North Carolina, United States, 28721-8046
      • Haywood Infusion Center
    • Pinehurst, North Carolina, United States, 28374
      • FirstHealth Outpatient Cancer Center
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • The Christ Hospital Cancer Center
  • Tennessee
    • Knoxville, Tennessee, United States, 37920
      • University of Tennessee Medical Center
  • Texas
    • Houston, Texas, United States, 77090
      • Millenium Research & Clinical Development
  • Wisconsin
    • Madison, Wisconsin, United States, 53715
      • SSM Health Cancer Care

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria (applicable to all participants unless otherwise specified):

• Cohort 1 only: Have histologically or cytologically confirmed ES-SCLC (using the American Joint Committee on Cancer [AJCC]) tumor node metastasis [TNM] staging system combined with Veterans Administration Lung Study Group two-stage classification scheme). For AJCC TNM staging system: AJCC 8th edition stage IV (T any, N any, M1a/b/c), or T3~4 for multiple lung nodules or tumor/nodule volume that cannot be encompassed in a tolerable radiotherapy plan.
• Cohort 1 only: Participants who have not received systemic therapy for ES-SCLC for various reasons including potential intolerance of the standard-of-care per the patient's treating physician's judgment. However, participants with prior chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) must have been treated with curative intent and had a treatment-free interval of at least 6 months since the last systemic anticancer treatment including chemotherapy, radiotherapy, or chemoradiotherapy before the diagnosis of ES-SCLC to be eligible.
• Cohort 2 and Cohort 3 only: Participants with SCLC who have disease progression/relapse after first-line platinum-based chemotherapy with or without immunotherapy, or after first-line platinum-based chemotherapy and one second-line of chemotherapy (not the same chemotherapy agent in the specific arm to be enrolled to) with time to progression ≥3 months during second-line treatment.
• Have given informed consent by signing and dating an informed consent form before initiation of any study-specific procedures.
• Male or female, aged ≥18 years at the time of giving informed consent.
• Are willing and able to comply with scheduled visits, treatment schedule, the planned study assessments, laboratory tests, lifestyle restrictions, and other requirements of the study. This includes that they are able to understand and follow study-related instructions.
• Have at least one measurable lesion as the targeted lesion based on RECIST 1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion).
• Eastern Cooperative Oncology Group performance status of 0 or 1.
• Have a minimum life expectancy of >3 months.

• Have adequate organ function, as defined below:

  • Hematology:

    • Absolute neutrophil count ≥1.5 × 10^9/L.
    • Platelet count ≥100 × 10^9/L.
    • Hemoglobin ≥90 g/L or 5.6 mmol/L.

  • Liver function:

    • Total bilirubin ≤1.5 × upper limit of normal (ULN).
    • With Gilbert's syndrome total bilirubin <3 mg/dL and direct bilirubin ≤ULN. Note, Gilbert's syndrome must be documented appropriately as past medical history.
    • Participants without liver metastasis alanine aminotransferase and aspartate aminotransferase ≤2 × ULN.
    • Participants with liver metastasis alanine aminotransferase and aspartate aminotransferase ≤5 × ULN.
    • Albumin ≥3.0 g/dL.
  • Renal function: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min. Cockcroft-Gault formula.
  • Qualitative urine protein ≤1+. If qualitative urine protein ≥2+, a 24-hour urine protein quantitative test is required. If the 24-hour urine protein result is <1 g, the participant can be enrolled.
  • Coagulation function: International normalized ratio or prothrombin time and activated partial thromboplastin time ≤1.5 × ULN unless the participant is receiving anticoagulation therapy as long as prothrombin or activated partial thromboplastin is within therapeutic range of intended use of anticoagulant.
• Are women of childbearing potential (WOCBP) who have a negative serum beta-human chorionic gonadotropin test at screening and before each IMP dose. Women born female that are postmenopausal (defined as 12 months with no menses without an alternative medical cause) or permanently sterilized (verified by medical records) will not be considered WOCBP and therefore will not be required to undergo pregnancy testing.
• Are WOCBP who agree to practice a highly effective form of contraception and to require their male sexual partners to use barrier contraception methods (preferably condoms), starting at Screening and continuously until 6 months after receiving the last study treatment.
• Are men who are sexually active with a partner born female and have not had a vasectomy who agree to use condoms and to ask their sexual partners to practice a highly effective form of contraception during the study, starting at the Screening Period and continuously until 6 months after receiving the last dose of IMP.
• Are WOCBP who agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study, starting at the Screening Period and continuously 6 months after receiving the last dose of IMP.
• Are men who are willing to refrain from sperm donation, starting at the Screening Period and continuously until 6 months after the last dose of IMP.

Exclusion Criteria (applicable to all participants):

• Are pregnant or breastfeeding or are planning pregnancy or planning to father children during the study or within 6 months after the last dose of IMP.
• Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the study, or that could prevent, limit, or confound the protocol-specified assessments or procedures, or that could impact adherence to protocol-described requirements.
• Have histologically or cytologically confirmed SCLC with combined histologies.

• Have received any of the following therapies or drugs within the noted time intervals prior to the initiation of study treatment:

  • Within 2 weeks: small molecule targeted agents with half-life of <7 days; or radiation not involving the thoracic cavity; local radiation for brain lesion is allowed; local radiation for bone lesions is allowed.
  • Within 4 weeks: radiation involving the thoracic cavity; small molecule targeted agents with half-life of ≥7 days; monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies.
  • Participants who received prior treatment with a PDL-1/VEGF bispecific antibody.
  • Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 10 days prior to the initiation of study treatment. Note: The following are allowed: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens).
  • Have been vaccinated with live attenuated vaccine(s) within 4 weeks prior to initiation of the study treatment.
  • Received broad-spectrum intravenous antibiotics therapy within 2 weeks prior to initiation of study treatment.
  • Use of any non-study IMP within 3 weeks before initiation of study treatment in this study or ongoing participation in the active treatment phase of another interventional clinical study.
• Have undergone major organ surgery (core needle biopsies are allowed >7 days prior study start), significant trauma, or invasive dental procedures (such as dental implants) within 28 days prior to the initiation of study treatment or plan to undergo elective surgery during the study. Placement of vascular infusion devices is allowed.
• Have received allogeneic hematopoietic stem cell transplantation or organ transplantation.

• Have the following central nervous system metastases:

  • Participants with untreated brain metastases that are symptomatic or large (e.g., >2 cm).
  • Participants who received treatment for central nervous system metastases are not neurologically stable or still on steroids 10 days before initiating IMP of this study.
  • Participants with known leptomeningeal metastases.
• Have active autoimmune disease or history of autoimmune diseases with anticipated relapse (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for those with clinically stable autoimmune thyroid disease or type 1 diabetes.
• Have had other malignant tumors within 2 years prior to the study treatment are not allowed. Except for those: who have been cured with local treatment (such as basal cell or squamous cell carcinoma of the skin, superficial or non-invasive bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, papillary carcinoma of thyroid and early stage prostate cancer).

• Have any of the following heart conditions within 6 months prior to the study treatment:

  • Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
  • New York Heart Association functional classification ≥II heart failure or left ventricular ejection fraction <50%.
  • Those who have ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrythmia/atrial fibrillation are allowed.
  • Mean QT interval corrected by Fridericia's method >480 ms (the electrocardiogram can be repeated at the discretion of the investigator).
  • Use of cardiac pacemaker.
  • Cardiac troponin I or T >2 x ULN.

• Have any of the following hypertension or diabetic conditions prior to initiation of study treatment:

  • Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) while on antihypertensive medicine.
  • Those with a history of hypertensive crisis or hypertensive encephalopathy.
  • Poorly controlled diabetes (fasting blood glucose ≥13.3 mmol/L [240 mg/dL]).
• Have serious non-healing wounds, ulcers, or bone fractures. This includes history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess for which an interval of 6 months must pass before enrollment into this study. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.

• Participants with evidence of major coagulation disorders or other significant risks of hemorrhage such as:

  • History of intracranial or intraspinal hemorrhage.
  • Tumor lesions invading large vessels and with significant risk of bleeding
  • Had clinically significant hemoptysis or tumor hemorrhage within 1 month prior to the initiation of study treatment.
• Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Participants with indwelling catheters (e.g., PleurX) are allowed. However, participants who are clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis or with indwelling catheters, e.g., PleurX) are allowed.
• Participants with a history of serious Grade 3 or higher immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy. Participants with a history of Grade ≥3 irAEs that did not lead to discontinuation of a prior immunotherapy but fully recovered may be enrolled per investigator's discretion. The investigator may request sponsor guidance in such cases.
• Have a known or suspected hypersensitivity to the study treatments including any active ingredient or excipients thereof.

• Have known human immunodeficiency virus infection or known acquired immunodeficiency syndrome, with the following exceptions:

  • Participants with cluster of differentiation 4 (CD4)+ T-cell (CD4+) counts ≥350 cells/µL per local laboratory should generally be eligible for the study.
  • Participants who have not had an opportunistic infection within the past 12 months.
• Have a known history/positive serology for hepatitis B requiring active antiviral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy). Individuals with positive serology must have hepatitis B virus viral load below the limit of quantification.
• Have an active hepatitis C virus infection; individuals who have completed curative antiviral treatment with hepatitis C virus viral load below the limit of quantification are allowed.
• Participants with AEs from prior antitumor therapy whose AE(s) have not returned to Grade 1 (graded by NCI CTCAE v5.0 criteria) or below (unless the investigator determines that certain AEs pose no safety risk to participants, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy) are not eligible for the study.
• Have superior vena cava syndrome or symptoms of spinal cord compression.
• Those with active, or a history of, pneumonitis requiring treatment with steroids, or has active, or a history of, interstitial lung disease. Those with a history of pulmonary fibrosis, or currently diagnosed with severe lung diseases such as interstitial pneumonia, pneumoconiosis, chemical pneumonitis, or any other condition resulting in significant impairment in lung function. Exception: Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.
• Have active tuberculosis.
• Have underlying condition(s) that may increase the risk of the combination treatment or complicate the interpretation of AEs, as judged by the investigator, or other scenarios in which the investigator consider the participant as not eligible for the study.
• Are vulnerable individuals, i.e., are individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. This includes all sponsor, study site, or third party (e.g., contract research organization, vendor) personnel directly involved in the conduct of the sudy and their family members or dependents, as well as all study site personnel otherwise supervised by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 Arm 1 - BNT327 DL1 + carboplatin + etoposide; Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting	Drug: Carboplatin; IV infusion; Drug: Etoposide; IV infusion; Drug: BNT327 Dose Level 1 (DL1); Intravenous (IV) infusion
Experimental: Cohort 1 Arm 2 - BNT327 DL2 + carboplatin + etoposide; Participants with ES-SCLC without prior systemic anticancer therapy received in the ES setting	Drug: Carboplatin; IV infusion; Drug: Etoposide; IV infusion; Drug: BNT327 Dose Level 2 (DL2); IV infusion
Experimental: Cohort 2 Arm 1 - BNT327 DL1 + paclitaxel; Participants with SCLC who have disease progression/relapse	Drug: Paclitaxel; IV infusion; Drug: BNT327 Dose Level 1 (DL1); Intravenous (IV) infusion
Experimental: Cohort 2 Arm 2 - BNT327 DL2 + paclitaxel; Participants with SCLC who have disease progression/relapse	Drug: Paclitaxel; IV infusion; Drug: BNT327 Dose Level 2 (DL2); IV infusion
Experimental: Cohort 3 Arm 1 - BNT327 DL1 + topotecan; Participants with SCLC who have disease progression/relapse	Drug: BNT327 Dose Level 1 (DL1); Intravenous (IV) infusion; Drug: Topotecan; IV infusion or oral capsules
Experimental: Cohort 3 Arm 2 - BNT327 DL2 + topotecan; Participants with SCLC who have disease progression/relapse	Drug: BNT327 Dose Level 2 (DL2); IV infusion; Drug: Topotecan; IV infusion or oral capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs	By treatment arm and overall.	up to 100 days after the last dose of treatment
Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs	In the combination treatment regimen according to the (US) National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0). By treatment arm and overall.	up to 100 days after the last dose of treatment
Objective Response Rate	Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment) is observed as best overall response. By treatment arm.	up to 24 months after completion of study treatment of the last participant
Best percentage change from baseline in the tumor size	Based on the investigator's tumor assessment according to RECIST 1.1. Defined as the change from baseline in percent to the minimal tumor size until tumor progression/recurrence or death (whichever comes first). By treatment arm.	up to 24 months after completion of study treatment of the last participant
Proportion of participants who have achieved early tumor shrinkage	Defined as ≥10% decrease in the pretreatment sum of diameters at first post-treatment tumor scan in target lesions. By treatment arm.	up to 2 months after first dose of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK assessment: Area under the curve during the dosing interval (AUCtau) values derived from serum concentration of IMP	By treatment arm. Only for the first cycle.	from pre-dose to 21 days after study treatment
Incidence of detectable BNT327 antidrug antibodies in serum	By treatment arm and overall.	from pre-dose to 100 days after last dose of study treatment
PK assessment: Maximum concentration (Cmax) derived from serum concentration of investigational medicinal product (IMP)	By treatment arm. Only for the first cycle.	from pre-dose to 21 days after study treatment
Duration of Response	Defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression or death from any cause, whichever occurs first based on investigator's review.	up to 24 months after completion of study treatment of the last participant
Disease Control Rate	Defined as the proportion of participants in whom a confirmed CR or PR or stable disease (per RECIST 1.1, stable disease assessed at least 6 weeks after first dose) is observed as best overall response based on the investigator's review.	up to 24 months after completion of study treatment of the last participant
Time to Response	Defined as the time from randomization to first objective response (CR or PR per RECIST 1.1) based on the investigator's review.	up to 24 months after completion of study treatment of the last participant
Progression-Free Survival (PFS)	Based on the investigator's tumor assessment according to RECIST 1.1. Defined as the time from randomization to first confirmed objective tumor progression (progressive disease per RECIST 1.1), or death from any cause, whichever occurs first.	up to 24 months after completion of study treatment of the last participant
PFS rate	As measured at 6, 12, 18, and 24 months	up to 24 months after completion of study treatment of the last participant
Overall Survival (OS)	Defined as the time from randomization to death from any cause	up to 24 months after completion of study treatment of the last participant
OS rate	As measured at 6, 12, 18, and 24 months	up to 24 months after completion of study treatment of the last participant

Collaborators and Investigators

• Sponsor: BioNTech SE
• Investigators: Study Director: BioNTech Responsible Person, BioNTech SE

Study record dates

Study Major Dates

• Study Start (Actual): August 5, 2024
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: June 3, 2024
• First Submitted That Met QC Criteria: June 3, 2024
• First Posted (Actual): June 7, 2024

Study Record Updates

• Last Update Posted (Actual): April 17, 2026
• Last Update Submitted That Met QC Criteria: April 16, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Combination chemotherapy; Time to progression; Programmed Death-1 (PD-1); Dose optimization; Programmed Death-1 monoclonal antibodies; Anti vascular endothelial growth factor (VEGF); Previously treated small-cell lung cancer; Untreated extensive-stage small-cell lung cancer; Programmed Death Ligand-1 (PD-L1)
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Small Cell Lung Carcinoma; Organic Chemicals; Heterocyclic Compounds; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Carbohydrates; Camptothecin; Alkaloids; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Glucosides; Glycosides; Coordination Complexes; Taxoids; Cyclodecanes; Diterpenes; Etoposide; Carboplatin; Paclitaxel; Topotecan
• Other Study ID Numbers: BNT327-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No